Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share - Schedule of potentially issuable common shares (Details)

v3.23.3
Net Loss Per Share - Schedule of potentially issuable common shares (Details) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total common stock equivalents 3,756,521 4,219,063 3,756,521 4,219,063
Conversion of Convertible Preferred Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total common stock equivalents [1]   855,186   855,186
Warrants to Purchase Common Stock and Redeemable Convertible Preferred Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total common stock equivalents [1] 853,330 853,330 853,330 853,330
PSUs, RSUs and Options to Purchase Common Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total common stock equivalents [1] 2,319,858 1,927,214 2,319,858 1,927,214
Right to Receive Earnout Shares [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total common stock equivalents [1] 583,333 583,333 583,333 583,333
[1] Prior period results have been adjusted to reflect the Reverse Stock Split at a ratio of 1-for-30 that became effective April 24, 2023. See Note 1, “Description of Business and Basis of Presentation,” for details.